Here is a look at Alzheimer’s disease, a progressive brain disorder that leads to loss of memory and other intellectual abilities. Facts Alzheimer’s disease is the most common form of dementia, which ...
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...
WashU Medicine-led trial evaluating investigational drug from Eli Lilly and Company aims to stop disease before symptoms ...
AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...
Monoclonal antibodies have emerged as a promising approach in the fight against Alzheimer's disease, offering hope for slowing its progression. T ...
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for ...
An international clinical trial aimed at preventing Alzheimer’s disease (AD) in young adults who are at risk of developing ...
Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...
Children who inherit genetic mutations from parents with early-onset Alzheimer’s typically show signs of dementia at the same ...
8d
Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...
Operator Ladies and gentlemen, thank you for standing by and welcome to the Lilly Q4 2024 earnings call. [Operator instructions] I would now like to turn the conference over to your host, Mike Czapar, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback